GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis
文献类型：期刊论文
| 作者 | Chen, Yan2; Xu, Ying-na2; Ye, Chen-yu2; Feng, Wen-bo2; Zhou, Qing-tong2; Yang, De-hua1,3,4 ; Wang, Ming-wei1,2,3,4,5
|
| 刊名 | ACTA PHARMACOLOGICA SINICA
 |
| 出版日期 | 2021-12-21 |
| 页码 | 11 |
| ISSN号 | 1671-4083 |
| 关键词 | NAFLD NASH GLP-1R GLP-1 mimetics dual agonists triple agonists GPCR |
| DOI | 10.1038/s41401-021-00836-9 |
| 通讯作者 | Yang, De-hua(dhyang@simm.ac.cn) ; Wang, Ming-wei(mwwang@simm.ac.cn) |
| 英文摘要 | Nonalcoholic steatohepatitis (NASH), as a severe form of nonalcoholic fatty liver disease (NAFLD), is characterized by liver steatosis, inflammation, hepatocellular injury and different degrees of fibrosis. The pathogenesis of NASH is complex and multifactorial, obesity and type 2 diabetes mellitus (T2DM) have been implicated as major risk factors. Glucagon-like peptide-1 receptor (GLP-1R) is one of the most successful drug targets of T2DM and obesity, and its peptidic ligands have been proposed as potential therapeutic agents for NASH. In this article we provide an overview of the pathophysiology and management of NASH, with a special focus on the pharmacological effects and possible mechanisms of GLP-1 mimetics in treating NAFLD/NASH, including dual and triple agonists at GLP-1R, glucose-dependent insulinotropic polypeptide receptor or glucagon receptor. |
| WOS关键词 | GLUCAGON-LIKE PEPTIDE-1 ; FATTY LIVER-DISEASE ; GASTRIC-INHIBITORY POLYPEPTIDE ; INDUCED HEPATIC STEATOSIS ; INSULIN-RESISTANCE ; RECEPTOR AGONIST ; ADIPOSE-TISSUE ; GUT MICROBIOTA ; LONG-TERM ; MITOCHONDRIAL-FUNCTION |
| 资助项目 | National Natural Science Foundation of China[81872915] ; National Natural Science Foundation of China[82073904] ; National Natural Science Foundation of China[81773792] ; National Natural Science Foundation of China[81973373] ; National Natural Science Foundation of China[21704064] ; National Science & Technology Major Project of China-Key New Drug Creation and Manufacturing Program[2018ZX09735-001] ; National Science & Technology Major Project of China-Key New Drug Creation and Manufacturing Program[2018ZX09711002-002-005] ; National Key Basic Research Program of China[2018YFA0507000] ; Science and Technology Commission of Shanghai Municipality[18431907100] ; Novo Nordisk-CAS Research Fund grant[NNCAS-2017-1-CC] ; SA-SIBS Scholarship Program |
| WOS研究方向 | Chemistry ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| 出版者 | NATURE PUBL GROUP |
| WOS记录号 | WOS:000732502400001 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/300791]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Yang, De-hua; Wang, Ming-wei |
| 作者单位 | 1.Res Ctr Deepsea Bioresources, Sanya 572025, Peoples R China 2.Fudan Univ, Sch Basic Med Sci, Dept Pharmacol, Shanghai 200032, Peoples R China 3.Chinese Acad Sci, CAS Key Lab Receptor Res, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China 4.Chinese Acad Sci, Natl Ctr Drug Screening, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China 5.ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China |
| 推荐引用方式 GB/T 7714 | Chen, Yan,Xu, Ying-na,Ye, Chen-yu,et al. GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis[J]. ACTA PHARMACOLOGICA SINICA,2021:11. |
| APA | Chen, Yan.,Xu, Ying-na.,Ye, Chen-yu.,Feng, Wen-bo.,Zhou, Qing-tong.,...&Wang, Ming-wei.(2021).GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis.ACTA PHARMACOLOGICA SINICA,11. |
| MLA | Chen, Yan,et al."GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis".ACTA PHARMACOLOGICA SINICA (2021):11. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。